This privacy notice describes how we collect and use your personal information, in accordance with the Data Protection Act and the General Data Protection Regulation.

Source: MHRA

Complex generic products are typically harder to develop, which means that many complex products face less competition than other products, and therefore can be more expensive and less accessible to the patients who need them.

Source: FDA

Goals agreed with the Medicines and Healthcare products Regulatory Agency to clarify how their actions should support economic growth.

Source: MHRA

Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to regulatory agencies.

Source: FDA

The Medicines and Healthcare products Regulatory Agency (MHRA) published a review of the safety of albumins manufactured from UK-sourced plasma with respect to variant Creutzfeldt-Jakob disease (vCJD) risk in August 2023.

Source: MHRA

Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Mirum Pharmaceuticals.

Source: FDA

The emerging safety concerns regarding hepatotoxicity associated with Epimedium brevicornu Maxim. could significantly impact its market perception and usage. Pharma strategy teams must closely monitor ongoing research and potential regulatory actions to mitigate risks and maintain consumer trust. Regulatory context from PMDA ([IBENTO][IBENTO]PMDA-ATC Herbal Medicine Seminar 2026) supports the near-term read. Assessment grounded in 24 ranked evidence items (2 high-relevance).

Source: Humanexa Insight

The approval of Resmetirom for MASH treatment represents a significant advancement in hepatology, highlighting a growing therapeutic area. Pharma companies must evaluate their portfolios for strategic alignment and potential competitive threats from this new entrant. Regulatory context from FDA (FDA Approves First Treatment for COVID-19) supports the near-term read. Assessment grounded in 20 ranked evidence items (7 high-relevance).

Source: Humanexa Insight

The initiation of Ipsen's trial for elafibranor in Primary Sclerosing Cholangitis represents a significant step in addressing an unmet medical need in a rare disease area. Successful trial outcomes could enhance Ipsen's position in hepatology and disrupt the competitive landscape among companies focused on liver diseases. Regulatory context from FDA (FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG)) supports the near-term read. Assessment grounded in 9 ranked evidence items (8 high-relevance).

Source: Humanexa Insight

The FDA's acceptance of the supplemental NDA for Terlivaz is a significant regulatory milestone that could strengthen Mallinckrodt's competitive position in the hepatology market. This development necessitates close monitoring of competitive responses and market dynamics as other companies may react to this advancement. Regulatory context from FDA (FDA AP — TERLIVAZ (SUPPL)) supports the near-term read. Assessment grounded in 9 ranked evidence items (2 high-relevance).

Source: Humanexa Insight

The development of a vitamin A-functionalized self-nanoemulsifying drug delivery system represents a significant advancement in targeting hepatic stellate cells for liver fibrosis treatment. This innovation could enhance treatment efficacy and provide a competitive edge in the hepatology market, necessitating further exploration by pharma companies. Regulatory context from MHRA (ACE-inhibitors: Be aware of the distinction between bradykinin- and histamine-mediated angioedema, as treatment strategies differ significantly) supports the near-term read.

Source: Humanexa Insight

Roche's launch of the Liver Disease Panel represents a significant advancement in digital health solutions for chronic liver disease, positioning the company as a leader in this space. This competitive move may compel other companies to enhance their own offerings, impacting market dynamics and innovation timelines. Regulatory context from MHRA (MHRA launches AI sandbox to accelerate medicines development and improve safety) supports the near-term read. Assessment grounded in 18 ranked evidence items (3 high-relevance).

Source: Humanexa Insight